Evidence map›Paper›PMID 42278213›Full record

ArticleInternational journal of molecular sciences2026

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

Cristina Aquilina, Andrea Romano, Anna Maria Corsale, Marta Biondo, Maria Speciale, Elena Tofacchi, Marta Di Simone, Emilia Gigliotta, Costanza Dieli, Claudia Avellone and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Cristina AquilinaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.ORCID 0009-0002-2759-3646
Andrea RomanoCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.ORCID 0009-0005-5467-4339
Anna Maria CorsaleDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-2541-4619
Marta BiondoHematology Section, Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
Maria SpecialeCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0001-8251-7537
Elena TofacchiDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Marta Di SimoneDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0003-1973-0540
Emilia GigliottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Costanza DieliCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.
Claudia AvelloneDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Angelo ToscanoGeneral Orthopedics, IRCCS Rizzoli Orthopedic Institute, 40136 Bologna, Italy.ORCID 0000-0003-0261-202X
Lawrence CamardaDepartment of Orthopaedics and Traumatology, University of Palermo, 90127 Palermo, Italy.
Alessandra RomanoHematology Section, Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
Daniela CambriaHematology Section, Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
Gianluca GiavaresiSurgical Sciences and Technologies, IRCCS Rizzoli Orthopedic Institute, 40136 Bologna, Italy.ORCID 0000-0001-7843-5969
Lavinia RaimondiSurgical Sciences and Technologies, IRCCS Rizzoli Orthopedic Institute, 40136 Bologna, Italy.ORCID 0000-0001-9394-2002
Antonino NeriScientific Directorate, Azienda USL-IRCCS of Reggio Emilia, 42122 Reggio Emilia, Italy.
Stefania CampanaDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Nadia CaccamoCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-1018-5710
Francesco DieliCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-6685-352X
Sergio SiragusaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Serena MeravigliaCentral Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-0383-5818
Cirino BottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-1522-4504

Funding

European Commission Mission Cancer (ELMUMY) 101097094European Union, Next Generation EU PNRR-MAD-2022-12376660My First Airc Grant (MFAG) 24534 (2021/2025)PRIN 2022 20229JM25NPRINN PNRR 2022 P202282S5M-PRO-MM-1PRIN PNRR 2022 P2022E2JSKSicilian MicronanoTech Research And Innovation Center (SAMOTHRACE) ECS00000022 CUP B63C22000900006
6 · The paper itself

Abstract

Multiple myeloma (MM) develops through asymptomatic precursor stages characterized by progressive remodeling of the bone marrow (BM) immune microenvironment and disruption of bone homeostasis. To delineate changes in natural killer (NK) cell states during disease evolution, we investigated coordinated immune-tumor remodeling by integrating NK cell functional states with plasma cell-intrinsic susceptibility programs derived from CRISPR-based screens across healthy donors (HD), monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and newly diagnosed MM patients. The integration of NK cell state-associated gene signatures with plasma cell transcriptional programs revealed stage-specific co-variation between immune and tumor compartments. Public single-cell RNA sequencing datasets were interrogated to resolve NK cell heterogeneity, identifying cytotoxic CD56

Indexed as

Killer Cells, NaturalMultiple MyelomaCD56 AntigenDisease ProgressionHumansMonoclonal Gammopathy of Undetermined SignificancePlasma CellsTumor MicroenvironmentCD56 Antigenmultiple myelomanatural killer cellsNK CD56brightsingle-cell RNA sequencing

Identifiers

PMID42278213
PMCPMC13256211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.